Dengue fever is the most important mosquito-borne viral disease in the world, for which preventive vaccines are urgently required. Several strategies have been used for dengue tetravalent vaccine development. Strategies with traditional attenuation, chimerization, engineered attenuation are in the more advanced stages. In addition, inactivated, subunit, virus-vectored, pseudo-infectious virus, and DNA vaccines have been developed. Although these strategies produced high levels of neutralizing antibodies against dengue virus types 1-4 and/or viremia protection following challenge in preclinical evaluations and clinical trials, concerns have been raised. This brief article focused on three strategies in the more advanced stages and reviewed the recent status of their development and the concerns against them.